الفهرس | Only 14 pages are availabe for public view |
Abstract In our study, RT dose escalation and OTT acceleration using SIB-IMRT technique in both definitive and postoperative setting in patients with stage III-IV HNC, could achieve a very good dose distribution and sparing of normal tissue and hence good results regarding outcome and pattern of toxicity. • SIB-IMRT as an altered fractionation schedule is safe in combination with systemic chemotherapy and/or Targeting therapy in treatment patients with stage III-IV HNC. • No statistically significant differences between patients who were treated with surgery followed by postoperative radiochemotherapy and those who received definitive radiochemotherapy, regarding PFS, LRFS, DMFS, and OS rates at 2 years. • The mean dose > 26 Gy to the contralateral parotid gland was predictor for persistent grade II xerostomia. • Oral cavity primary tumor site, advanced T3-T4 stage, advanced N2c-N3 disease, and RT interruption were associated with LRF. • The role of neoadjuvant chemotherapy in patients with stage III-IV HNC needs further investigation. |